PB2304: FIVE-YEAR SUBGROUP ANALYSIS OF TAFASITAMAB + LENALIDOMIDE FROM THE PHASE II L-MIND STUDY IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA

• Johannes Duell,
• Pau Abrisqueta,
• Martin Dreyling,
• Gianluca Gaidano,
• Eva González Barca,
• Wojciech Jurczak,
• Anna Marina Liberati,
• Kami Maddocks,
• Tobias Menne,
• Zsolt Nagy,
• Olivier Tournilhac,
• Abhishek Bakuli,
• Aasim Amin,
• Konstantin Gurbanov,
• Gilles Salles

Affiliations

Johannes Duell

1 Medizinische Klinik und Poliklinik II, Würzburg, Germany

Pau Abrisqueta

2 Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron University Hospital, Barcelona, Spain

Martin Dreyling

3 University Hospital Munich – Grosshadern, Ludwig-Maximilians-University Hospital, Munich, Germany

Gianluca Gaidano

4 Division of Hematology, Department of Translational Medicine & IRCAD, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy

Eva González Barca

5 Institut Català d’Oncologia, Hospital Duran i Reynals, Barcelona University, Barcelona, Spain

Wojciech Jurczak

6 Department of Clinical Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, Kraków, Poland

Anna Marina Liberati

7 Università degli Studi di Perugia, Terni, Italy

Kami Maddocks

8 Department of Internal Medicine, Arthur G James Comprehensive Cancer Center, Ohio State University Wexner Medical Center, Ohio, United States

Tobias Menne

9 Freeman Hospital, The Newcastle upon Tyne Hospitals, NHS Foundation Trust, Tyne, United Kingdom

Zsolt Nagy

10 Semmelweis University, Budapest, Hungary

Olivier Tournilhac

11 CHU de Clermont-Ferrand, 58 Rue Montalembert, Lyon, France

Abhishek Bakuli

12 MorphoSys AG, Planegg, Germany

Aasim Amin

12 MorphoSys AG, Planegg, Germany

Konstantin Gurbanov

12 MorphoSys AG, Planegg, Germany

Gilles Salles

13 Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, United States